Voisin Consulting Life Sciences Names Mark A. De Rosch, PhD, to Lead US Operations

  Voisin Consulting Life Sciences Names Mark A. De Rosch, PhD, to Lead US
  Operations

Business Wire

CAMBRIDGE, Mass. & PARIS -- October 9, 2013

Voisin Consulting Life Sciences, a leading drug development consultancy,
announced the appointment of Mark A. De Rosch, PhD, as vice president of
Regulatory Drugs/Biologics and head of US Operations. Dr. De Rosch is
responsible for providing strategic counsel to pharmaceutical and biotech
companies with product and drug pipeline development globally. He also is
leading Voisin’s US-based regulatory team.

Voisin Consulting Life Sciences, a leading drug development consultancy,
announced the appointment o ...

Voisin Consulting Life Sciences, a leading drug development consultancy,
announced the appointment of Mark A. De Rosch, PhD, as vice president of
Regulatory Drugs/Biologics and head of US Operations.

“Mark is a great fit, as he has sound product expertise, broad regulatory
experience, and a successful track record in designing and executing global
regulatory strategies," said Emmanuelle M. Voisin, PhD, Voisin Consulting Life
Sciences founder and CEO.

“Mark’s track record and expertise strengthens our capabilities to provide
clients with a global regulatory perspective, from strategic to tactical
operations in moving drugs and biologics from research to development and
through commercialization. Mark's success in working with FDA from the pre-IND
stage through product approval and his experience in building strong
regulatory teams is a tremendous asset for our clients who wish to develop
their products synergistically in the US and Europe. I am excited about the
contributions that he will make in his senior management role,” Dr. Voisin
said.

Dr. De Rosch's expertise lies in development of regulatory strategies for
drugs and biologics, especially including orphan and pediatric diseases, which
are two of Voisin Consulting Life Sciences' core strengths. Dr. De Rosch
brings more than 20 years experience at leading pharmaceutical and biotech
companies, such as Vertex Pharmaceuticals, where he was deeply involved in the
regulatory approval of Kalydeco® and was involved in regulatory activities for
development of Incivek®. He has proven expertise from pre-IND through NDA and
post-marketingin the US and EU, as well as other markets including Canada and
Australia. Dr. De Rosch has deep experience in several therapeutic areas,
including hematology, respiratory, auto-immune/rheumatology, oncology, pain,
renal, and medical imaging/radiopharmaceuticals.

“I am delighted to join Voisin Consulting Life Sciences, with whom I have
worked with for many years as a client. I am pleased to become part of an
enthusiastic group, at the cutting-edge of science, regulation and marketing.
I look forward to contributing to the growth opportunity for the organization
in assisting pharmaceutical and biotech clients in navigating FDA regulations.
From our US office located in Kendall Square in Cambridge, Mass., our FDA
expertise will add appreciable value to both US- and non-US-based clients,"
said Dr. De Rosch.

About Voisin Consulting Life Sciences

Voisin Consulting Life Sciences is a product development consultancy, which
provides biotech, pharma and medtech companies with combined strategic and
operational capabilities for interacting with regulators and payers. With a
presence in the US, France, Switzerland, the UK, Singapore and India, the firm
specializes in drugs, biologics, cell, gene and tissue-engineering therapies,
medical devices/IVD/theranostics, combination products, borderline products
and bioactives/food supplement. Voisin Consulting Life Sciences also has an
active regulatory publishing group and supports electronic submissions through
both the FDA and EMA gateways. The firm also has extensive experience in
assisting companies with scientific advice meetings with regulatory agencies
such as FDA, EMA, and EU National Agencies. For more information, visit
www.voisinconsulting.com.

Photos/Multimedia Gallery Available:
http://www.businesswire.com/multimedia/home/20131009005362/en/

Multimedia
Available:http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50725195&lang=en

Contact:

Media Contacts:
LaVoie Strategic Communications Group
David Connolly, 617-374-8800, ext. 104
dconnolly@lavoiegroup.com
or
Samantha Stenbeck, 617-374-8800, ext. 102
sstenbeck@lavoiegroup.com
or
Voisin Consulting Life Sciences
US Corporate Contact:
Mark De Rosch, PhD, +1-617-492-1537
vccambridge@voisinconsulting.com
or
European Corporate Contact:
Emmanuelle M. Voisin, PhD, +33 (0)1 41 31 83 00
vcparis@voisinconsulting.com
 
Press spacebar to pause and continue. Press esc to stop.